

RESEARCH OPPORTUNITY

NAMI is committed to ensuring that the most effective treatments for mental illness are available to those who need them. Determining which treatments are most effective requires research. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and Chief Program Officer Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved by an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting clinical trial participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these trials. If you have questions about research at NAMI, please visit NAMI.org/research or email us at research@nami.org.

WHAT IS THE STUDY?

This study is a clinical research trial for the investigational drug, BI 1358894. The trial will determine if the investigational drug is safe and effective for reducing symptoms of PTSD. Participants will be randomly assigned to receive either the oral investigational drug or placebo over a period of eight weeks. The goal of this study is to increase treatment options available for people experiencing PTSD.

WHO CAN PARTICIPATE?

Individuals may be eligible for this study if they:

- Are aged 18-65 and diagnosed with PTSD as primary psychiatric diagnosis
- Experienced the traumatic event at least 3 months before the screening visit
- Have never met diagnostic criteria for schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar disorder, delusional disorder, brief psychotic disorder, or any other psychotic disorder, as well as MDD with psychotic features

Individuals are not eligible for this study if they:

- Have a positive urine drug screen at the screening visit and are not willing to abstain (quit) from using marijuana for the duration of the study

There will be about 300 people with PTSD participating in this study worldwide. Total participation time is approximately 16 weeks, including screening, treatment, and follow-up. Participants may receive reimbursement for travel expenses and additional compensation may apply.

WHERE IS THE STUDY TAKING PLACE?

There are multiple study sites located across the U.S. For a list of study site locations, please visit the study website: <http://www.ptsd-nami.com>

HOW DO I LEARN MORE?

The documents attached have additional information about the study. If you have questions or would like more information, please refer to the study website: <http://www.ptsd-nami.com>